Login
$GPCR
$21.55 +$0.45 (2.13%) Close

Company Executives

$GPCR Management Team

Ms. Ashley Hall

Chief Development Officer

Age 52
Compensation -
Sex Female

Dr. Yingli Ma

Chief Technology Officer

Age 51
Compensation $1.242M USD
Sex Female

Dr. Blai Coll

Chief Medical Officer

Age 51
Compensation $3.451M USD
Sex Male

Mr. Daniel Welch

Independent Chairman of the Board

Age 67
Compensation $643.7K USD
Sex Male

Dr. Raymond Stevens

Chief Executive Officer

Co-Founder

Director

Age 61
Compensation $5.739M USD
Sex Male

Mr. Jun Yoon

Chief Financial Officer

Co-Founder

Age 47
Compensation $3.675M USD
Sex Male

Dr. Xichen Lin

Chief Scientific Officer

Age 51
Compensation $3.691M USD
Sex Male
Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
4.0 years
from year joined
CEO also chairs the board
No
Daniel G. Welch
Director Age On board Independent Committees Other public boards 2025 pay Source
Ted W. Love
67 2023
3 years
Independent None stated Gilead Sciences, Inc. $357,525
Raymond Stevens
62 2019
7 years
Not stated None stated Danaher Corporation Paid as CEO
Daniel G. Welch
68 Not stated Independent None stated Ultragenyx Pharmaceuticals Inc., Prothena Corporation plc $531,525
Angus C. Russell
70 2024
2 years
Independent
Audit
Lineage Cell Therapeutics, Inc. $294,806
Sharon Tetlow
66 2022
4 years
Independent None stated None stated $360,025
Eric Dobmeier
57 2022
4 years
Independent None stated Janux Therapeutics, Inc. $352,525
Joanne Waldstreicher
66 2022
4 years
Independent None stated Becton Dickinson and Company $355,025

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 23, 2026
Entities associated with Avoro
a beneficial owner of greater than 5% of our Ordinary Shares
$14,999,744

Purchase of 4,615,386 Pre-Funded Warrants in the December 2025 follow-on offering, on the same terms as outside investors

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support